ADA Scientific Sessions 2026 Abstract

Harmony: A Head-to-Head Phase 3 Study of HTD1801 vs. Dapagliflozin

By Linong Ji, Zhifeng Cheng, Hanqing Cai, Liping Liu

Trial in peopleInterventions

The paper

Beijing

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 1781-P

doi.org/10.2337/db26-1781-p

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity